# Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants

> **NCT07258745** · PHASE1 · RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 213 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** SKYRIZI
- **BIOLOGICAL:** SKYRIZI
- **BIOLOGICAL:** CKD-704

## Key facts

- **NCT ID:** NCT07258745
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-26
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 213 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07258745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07258745, "Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07258745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*